Merck Sharp & Dohme Corp. – Metastatic Melanoma

Access Program Information

<p>This is an expanded access program (EAP) for participants who have progressed after prior systemic therapy including <strong>ipilimumab</strong>, and <strong>V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor</strong> or <strong>mitogen-activated protein kinase (MEK) enzyme inhibitor</strong> when indicated. Participants cannot be eligible for or have participated in any pembrolizumab (MK-3475) clinical trial.</p>

Rare Disease: